Experts warn of health risks as Miami-Dade brush fire continues to burn
Even if the air looks clear, being outside near a
large brush fire
isn't safe, experts warn.
A
massive brush fire
in southwest Miami-Dade is raising concerns about air quality and doctors say exposure, even without visible smoke, can be dangerous.
Dr. Samuel Gurevich, a lung and critical care specialist at Cleveland Clinic, said this fire is more hazardous than last week's because of how noticeable it is. That means greater risks for anyone breathing in the smoke.
"Things can look completely clear, and wind shifts very quickly," Gurevich said. "In a matter of minutes, you get exposure."
The American Lung Association warns that inhaling smoke can affect anyone, not just those with pre-existing lung conditions.
Smoke exposure can inflame the lungs, and depending on what's burning, it may even release cancerous materials into the air.
Local residents said they can see, smell and feel the smoke.
"It's in your nose," said Melissa Murrell, who lives nearby. "My eyes are burning now."
She has been limiting her time outside, only going out to walk her new puppy.
"There's ashes falling in the grass, and I don't want her to get sick," Murrell said.
Miami-Dade Fire Rescue is urging residents to stay indoors as crews work to contain the fire. Florida Highway Patrol officials say the fire will likely burn for several more days.
For those in affected areas, Gurevich recommends staying in a car or wearing an N95 mask if sensitive to smoke.
"You don't want this to be your first experience in finding out you have asthma," he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
Person dead, another hospitalized after welfare check at trailer in rural Miami-Dade County, sheriff's office says
One person is dead and another was hospitalized in critical condition following a welfare check at a trailer parked in rural southwestern Miami-Dade County early Thursday morning, the sheriff's office said. Around 12:45 a.m., Miami-Dade Sheriff's deputies responded to the area near Southwest 232nd Street and 204th Avenue for a welfare check at a trailer. Upon arrival, deputies saw an "unconscious male" from the bedroom window, MDSO said. MDSO added that one person was declared dead at the scene and another person was taken to Jackson South Community Hospital in critical condition. MDSO did not specify how the man seen from the window was related to the investigation, or whether he was the deceased or the hospitalized victim. MDSO's Homicide Unit is investigating the circumstances surrounding the death. This is a developing story. Please check back for updates.
Yahoo
4 hours ago
- Yahoo
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP:
Business Wire
5 hours ago
- Business Wire
Lineage Cell Therapeutics Announces Updates to the 3 rd Annual Spinal Cord Injury Investor Symposium
CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or 'off the shelf', cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3 rd Annual Spinal Cord Injury Investor Symposium ("3 rd SCIIS"). The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025. 'We are excited by the incredible response by presenters that have confirmed to date and believe that our third symposium will offer attendees the most comprehensive and relevant discussions related to the field of spinal cord injury we have been able to assemble to date,' stated Brian M. Culley, Lineage CEO. 'We believe collaborative problem-solving is an integral component to the goal of supporting individuals living with SCI and we are proud to bring together a diverse and broad array of clinical and preclinical companies, thought leader perspectives, and most importantly, insights from persons with lived experience. This event will be open and accessible online at no cost, and we invite you to register directly through the symposium website and to join us for the virtual event on June 27 th as we again assemble a unique group of forward-thinking leaders in SCI product development.' Current confirmed thought leaders, persons with lived experience and moderating healthcare analysts (subject to change): Armin Curt, M.D., Full Professor for Paraplegiology and Medical Director, Balgrist University Hospital, Zurich, Switzerland Richard G. Fessler, M.D., Ph.D., Professor, Department of Neurosurgery, RUSH University Medical Center James D. Guest, M.D., Ph.D., Clinical Professor, Department of Neurological Surgery, The Miami Project to Cure Paralysis, Professor, University of Miami Miller School of Medicine Steven Kirshblum, M.D., Chief Medical Officer, Kessler Foundation, Professor of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical School Edelle Field-Fote, PT, Ph.D., FAPTA, FASIA, Director, Spinal Injury Research & The Hulse Spinal Injury Laboratory, Shepherd Center John (Kip) Kramer, Ph.D., Associate Professor, Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia Monica A. Perez, PT, Ph.D., Scientific Chair, Arms + Hands Lab, Shirley Ryan AbilityLab, Professor of Physical Medicine and Rehabilitation, Northwestern University Jeffrey C. Petruska, Ph.D., Associate Professor, University of Louisville, Department of Anatomical Sciences and Neurobiology Jerod & Hanna Nieder, Positively Paralyzed, LLC Robert Paylor, Motivational Speaker and Author , Executive Director, Portfolio Strategy & Governance, BeOne Medicines USA Barry Munro B.A., LLB., Chief Development Officer, Canadian Spinal Research Organization Jack Allen, CFA, Senior Research Analyst, Biotechnology, R.W. Baird & Co., Inc. Joseph Pantginis, Ph.D., Director of Research, Managing Director, Equity Research, H.C. Wainwright & Co., Inc. Current corporate presenters (subject to change): The 3 rd Annual Spinal Cord Injury Investor Symposium will be a fully virtual event open to all participants, with interactive and on-demand sessions available on June 27, 2025. This event will bring together both public and private companies developing new treatment options for people with spinal cord injury, alongside leaders in the spinal cord injury medical and advocacy communities. A number of important topics will be discussed, including but not limited to preclinical and clinical SCI treatment approaches and the drug development process; racial, ethnic, socioeconomic, geographic vulnerabilities within SCI care and outcomes; hearing the persons with lived experience voice and ensuring patient's perspectives, needs and priorities are captured in the drug development process; and discussions of SCI clinical endpoints and the need for new and more precise assessment tools. For more information, please visit or follow the event on X/Twitter @SCISymposium. About Spinal Cord Injuries A spinal cord injury occurs when the spinal cord is subjected to a severe crush or contusion and frequently results in severe functional impairment, including limb paralysis, aberrant pain signaling, and loss of bladder control and other body functions. There are approximately 18,000 new spinal cord injuries annually in the U.S. The cost of a lifetime of care for a severe spinal cord injury can be as high as $5 million. About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, or 'off the shelf', cell therapies for serious neurological and ophthalmic conditions. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen ®, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonance (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed under a gene editing partnership. For more information, please visit or follow the company on X/Twitter @LineageCell. Forward-Looking Statements Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," 'aim,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'design,' 'intend,' 'expect,' 'could,' 'can,' 'plan,' 'potential,' 'predict,' 'seek,' 'should,' 'would,' 'contemplate,' 'project,' 'target,' 'tend to,' or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to: the potential effect of the 3 rd SCIIS. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, those risks and uncertainties inherent in Lineage's business and other risks discussed in Lineage's filings with the Securities and Exchange Commission (SEC). Lineage's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading 'Risk Factors' in Lineage's periodic reports with the SEC, including Lineage's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
